Work

Review of radiopharmaceutical therapy in prostate cancer

Year: 2026

Type: article

Abstract: Radiopharmaceuticals therapy (RPT) has been a major breakthrough in the treatment of prostate cancer. This therapy utilizes radioactive isotopes targeted specifically to prostate cancer, combining the advantages of systemic therapy with targeted radiation. The 2 currently FDA approved agents are 223 Ra and 177 Lu-PSMA-617 which have both demonstrated an overall survival advantage. In this review we will discuss the approved agents, their similarities and differences, treatment sequencing, combinations with other therapies, as well as future directions of this promising field.

Source: Urologic Oncology Seminars and Original Investigations

DOI: 10.1016/j.urolonc.2026.111030

Authors: Sean R. Miller, Yuni Dewaraja, Steven P. Rowe, Zachery R. Reichert, Benjamin L. Viglianti

Institutions: University of Michigan, Michigan Medicine, The University of Texas Southwestern Medical Center

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,440